The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 5, 2025. Its latest SEC filing is a 15-12G from Feb 20, 2026.
10-Q for Q3 FY2025, filed Nov 5, 2025
The sections below describe the company as of the FY2024 annual report.
Sells an adult hepatitis B vaccine to healthcare distributors and develops vaccine candidates and adjuvants with vaccine developers.
10-K for FY2024, filed Feb 20, 2025We are a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against…View ↗
Our first marketed product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States ("U.S."), the…View ↗
We are advancing a pipeline of differentiated product candidates that leverage our CpG 1018 adjuvant to develop improved vaccines in…View ↗
Additionally, we manufacture and have supplied in the past CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B, through both commercial…View ↗
All of our HEPLISAV-B sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include independent…View ↗
In the U.S., wholesalers and specialty distributors buy HEPLISAV-B for resale to hospitals, clinics, public health and government facilities, and pharmacies; one distributor buys it in Germany. Vaccine developers also work with Dynavax on CpG 1018 supply and research collaborations.
10-K for FY2024, filed Feb 20, 2025All of our HEPLISAV-B sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include independent…View ↗
All of our HEPLISAV-B sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include independent…View ↗
Additionally, we manufacture and have supplied in the past CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B, through both commercial…View ↗
Yes. It kept 10 cents of every revenue dollar as net income in FY2024 and turned 22 cents into free cash flow.
10-Q for Q3 FY2025, filed Nov 5, 2025
Open tableView ↗
8-K, filed Feb 10, 2026
The consummation of the Merger constitutes a Share Exchange Event, a Fundamental Change and a Make-Whole Fundamental Change (each as…View ↗
8-K, filed Dec 29, 2025
On December 23, 2025, Dynavax Technologies Corporation, a Delaware corporation (the “Company” or “Dynavax”), entered into an Agreement and…View ↗
8-K, filed Nov 5, 2025
HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; reiterates full year 2025 HEPLISAV-B® net product revenue…View ↗
Competes with Pfizer, BioNTech, Curevo Vaccine, Moderna, GSK, Merck, VBI Vaccines, Sanofi, Bavarian Nordic, Emergent BioSolutions, Novavax, Medicago, Valneva, AstraZeneca, and Johnson & Johnson
10-K for FY2024, filed Feb 20, 2025The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong…View ↗
Loading...